Immatics Announces Second Quarter 2025Â Financial Results and Business Update
Houston, Texas and Tuebingen, Germany, August 13, 2025 â Immatics N.V. (NASDAQ: IMTX, âImmaticsâ or the âCompanyâ), a clinical-stage biopharmaceutical company and the global leader in precision tar...
How might macroeconomic factors or broader market trends affect the performance of Immatics' stock following this earnings release?
Are there any upcoming regulatory or FDA filing milestones that could drive volatility in the stock?
What is the anticipated impact of any partnership, licensing, or collaboration announcements on future revenue streams?
28 days ago